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Background: The phosphatidylinositol 3-kinase (PI3K) pathway plays an important role in multiple myeloma (MM),
a blood cancer associated with uncontrolled proliferation of bone marrow plasma cells. This study aimed to
develop a robust clinical pharmacodynamic (PD) assay to measure the on-target PD effects of the selective PI3K
inhibitor GDC-0941 in MM patients.
Methods: We conducted an in vitro drug wash-out study to evaluate the feasibility of biochemical approaches in
measuring the phosphorylation of S6 ribosomal protein (S6), one of the commonly used PD markers for PI3K
pathway inhibition. We then developed a 7-color phospho-specific flow cytometry assay, or phospho flow assay, to
measure the phosphorylation state of intracellular S6 in bone marrow aspirate (BMA) and peripheral blood (PB).
Integrated mean fluorescence intensity (iMFI) was used to calculate fold changes of phosphorylation. Assay
sensitivity was evaluated by comparing phospho flow with Meso Scale Discovery (MSD) and immunohistochemistry
(IHC) assays. Finally, a sample handling method was developed to maintain the integrity of phospho signal during
sample shipping and storage to ensure clinical application.
Results: The phospho flow assay provided single-cell PD monitoring of S6 phosphorylation in tumor and surrogate
cells using fixed BMA and PB, assessing pathway modulation in response to GDC-0941 with sensitivity similar to
that of MSD assay. The one-shot sample fixation and handling protocol herein demonstrated exceptional
preservation of protein phosphorylation. In contrast, the IHC assay was less sensitive in terms of signal
quantification while the biochemical approach (MSD) was less suitable to assess PD activities due to the undesirable
impact associated with cell isolation on the protein phosphorylation in tumor cells.
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Conclusions: We developed a robust PD biomarker assay for the clinical evaluation of PI3K inhibitors in MM,
allowing one to decipher the PD response in a relevant cell population. To our knowledge, this is the first report of
an easily implemented clinical PD assay that incorporates an unbiased one-shot sample handling protocol, all
(staining)-in-one (tube) phospho flow staining protocol, and an integrated modified data analysis for PD monitoring
of kinase inhibitors in relevant cell populations in BMA and PB. The methods described here ensure a real-time,
reliable and reproducible PD readout, which can provide information for dose selection as well as help to identify
optimal combinations of targeted agents in early clinical trials.
Keywords: Phosphatidylinositol 3-kinase, Pharmacodynamics, Biomarker, Multiple myeloma, Immunohistochemistry,
Meso Scale Discovery, Flow cytometry, Clinical trialBackground
Multiple myeloma (MM), also known as myeloma or
plasma cell myeloma, is a B cell neoplasm characterized
by monoclonal plasma cell expansion localized in the bone
marrow. MM is the second most prevalent hematologic
malignancy after non-Hodgkin’s lymphoma. It represents
approximately 1% of new cancer cases and 2% of cancer
deaths in the United States, with an estimated 21,700 new
cases and 10,710 cancer deaths in 2012 [1]. In recent
years, the overall survival of myeloma patients has im-
proved to 7 to 8 years due to the widespread use of several
novel agents (Bortezomib, lenalidomide and thalidomide)
and the incorporation of autologous hematopoietic stem
cell transplantation. However, the etiology and the mech-
anism of disease development of MM are still incom-
pletely understood.
The pathogenesis of MM involves multistep genetic
and microenvironmental changes, including chromo-
some abnormalities (translocations and deletion) and
de-regulation of oncogenic signaling pathways [1]. The
activation of growth factor pathways such as interleukin
6 (IL-6) and insulin-like growth factor I (IGF-I) have been
found to activate the downstream phosphatidylinositol
3-kinase (PI3K)-AKT signaling cascade in MM [2]. In fact,
late-stage MM tumors exhibit dramatically enhanced
AKT activation [3], and inhibition of the PI3K-AKT path-
way has been effective in preclinical studies of MM [2-6].
Decades of studies have provided the rationale for testing
PI3K inhibitors, such as GDC-0941, in cancer prevention
and treatment [7-9]. Currently, small molecule inhibitors
targeting PI3K and AKT (Perifosine) pathways are being
evaluated in clinical trials of MM [10].
Robust tumor PD assays would be useful for the clin-
ical evaluation of GDC-0941 in myeloma patients.
Among others, IHC is the current gold-standard PD
assay routinely used in clinical trials, while Meso Scale
Discovery (MSD) is one of the most sensitive biochem-
ical assays in PD studies. Reduced phosphorylation of
downstream proteins, including S6, is a commonly used
proof-of-mechanism of PI3K pathway inhibition [8,11].GCD-0941 is a potent oral pan-PI3K inhibitor that has
demonstrated reduced phosphorylation of downstream
proteins including S6 ribosomal protein (pS6) in tumor
cells by IHC in Phase I studies of patients with solid tu-
mors [12]. From a tumor PD perspective, there are
intrinsic caveats with IHC or MSD assays to assess the
protein phosphorylation of S6 in MM [10], a blood cancer
whose tumor cells reside within the bone marrow with
variable tumor content between 5-95% in newly diagnosed
patients.
Protein phosphorylation is a transient event that can
be preserved by formalin-containing fixatives and cap-
tured by flow cytometry-based phospho flow, an assay
particularly suitable for studying the phosphorylation
status in a complex cell population such as BMA or PB.
In this study we adapted a phospho flow cytometric
method to develop a robust phospho flow-based PD
assay for the clinical evaluation of PI3K inhibitors in
MM, monitoring protein phosphorylation and pathway
modulation in the relevant cell types.
Methods
Materials
Test compound GDC-0941 was synthesized at Genentech.
Stock solutions of GDC-0941 were prepared in DMSO
and diluted in the indicated culture medium for the treat-
ment of cells or directly added into bone marrow aspirate
(BMA) and/or peripheral blood (PB) (final concentration
of DMSO, <0.1%).
Cell culture
MM1s and RPMI 8226 cell lines were maintained in RPMI
1640 media supplemented with 10% fetal bovine serum
(FBS) and 1 mM glutamine (Sigma-Aldrich) at 37°C in a
humidified incubator containing 5% CO2. Fresh BMA and
PB were obtained from healthy donors at Genentech or
from myeloma patients at a local clinic with appropriate
informed consents for exploratory biomarker evaluation.
Whole blood or BMA were collected in heparinized
vacutainers, and transported to the laboratory within 3
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cells, BMA, or PB) were treated with DMSO or GDC-
0941 ex vivo at 37°C in a humidified incubator with
21% O2 and 5% CO2.
Phospho-specific flow cytometry
After incubation, the samples (tumor cells, BMA, PB)
were immediately fixed for 10 minutes by adding 1×
lyse/fix buffer (BD Biosciences) at room temperature
(RT), and then permeabilized with cold 100% methanol
on ice for 10 min. After washing with phosphate buff-
ered saline (PBS) and FBS based staining buffer, approxi-
mately one million cells per tube were stained for 30
minutes in the dark with an antibody cocktail prior to
flow cytometric analysis.
Blood lineage-specific surface CD markers were
stained with the following antibodies: CD45 Alexa 700
(HI30), CD14 Alexa 488 (M5E2), CD38 V450 (HB7),
CD138- PE (MI15), CD20 PerCP-Cy5.5 (2H7), CD3
PE- Cy7 (SKY7), (BD Biosciences). Intracellular phospho-
protein was stained using a specific monoclonal antibody
against pS6 Ser235/236 Alexa 647 (Cell Signaling). The
primary antibodies were diluted at the optimal dilution
according to the manufacturer’s instructions.
Appropriate isotype controls for cell surface markers
and rabbit (DA1E) mAb IgG XPW Isotype Control (Alexa
FluorW 647 Conjugate) for pS6 were used to facilitate the
gating of specific cell populations of interest. QC of the
FACSCAntoII instrument was preformed on each day of
the study. A set of BD anti-mouse Ig, k/negative control
(FBS) CompBeads was used to optimize the fluores-
cence compensation setting necessary for multicolor
flow cytometric analyses. At least 10,000 cell events
were collected and analyzed on a BD FACSCanto II sys-
tem (BD Biosciences). Flow cytometry analysis was carried
out using FACSDiva Software and Prism 4.0 (GraphPad).
To minimize day-to-day variation in cytometer settings
and perform daily QC, CST beads with fluorescence in all
channels (BD Biosciences) were tested at the beginning of
each acquisition run. Fluorescence values varied by <10%
of target values. For the assay reproducibility study, BMA
and PB samples from the same donor were separated into
multiple replicates for phospho flow analysis.
MSD
Cells were washed with phosphate buffered saline (PBS),
lysed with MSD lysis buffer and incubated on ice for 30
minutes. Soluble proteins were collected by spinning at
20000g for 10 minutes. Equal amounts of protein (20
ug) were added into each well of pS6 (S235/236)/total
S6 MSD plate (Cat# K150DFD-3; Meso Scale Discovery,
LLC), and MSD assays were performed according to the
manufacturer’s instructions.IHC staining and pS6 quantification
MM1s cells (8 × 107 cells) were treated with GDC-0941
for 2 hrs at each of the indicated concentrations. Cells
were washed once with cold PBS and cell pellets were
fixed in buffer neutralized formalin overnight prior to
paraffin embedding.
Immunohistochemistry (IHC) was performed on 4 μm
thick formalin-fixed paraffin embedded tissue sections
mounted on glass slides. All IHC steps were carried out
on the Ventana Discovery XT (Ventana Medical Systems;
Tucson, AZ) autostainer. Pretreatment was done with Cell
Conditioner 1, standard time. Primary antibody, anti-
phospho-S6 (Rabbit polyclonal, 2211L, Cell Signaling
Technologies, Cambridge, MA) was used at a concentra-
tion of 0.26 μg/ml and was incubated on slides for 32
minutes at 37°C, followed by incubation with Ventana
Ultramap-HRP for 16 minutes. Ventana DAB and
Hematoxylin II were used for chromogenic detection
and counterstain.
Whole slide images were acquired by the Olympus
Nanozoomer automated slide scanning platform
(Hamamatsu, Bridgewater, NJ) at 200× final magnifica-
tion. Scanned slides were analyzed in the Matlab software
package (version R2011b by Mathworks, Natick, MA) as
24-bit RGB images. Cellular area was identified using in-
tensity thresholding and standard morphological filtering.
The brown DAB-specific staining was identified using a
blue-normalization algorithm as described by Brey et al.
[13]. The optical density of DAB staining was calculated
using the Beer-Lambert law, absorbance = −log (transmit-
ted light / incident light), on DAB positive areas only.
Statistical analysis
The concentration of drug resulting in 50% maximal
inhibitory concentration (IC50) was determined using
Prism software (GraphPad). All statistical analyses were
conducted with the Student t test and are represented
as mean ± SD. One asterisk indicates p < 0.05, and two
asterisks indicate p < 0.01.
Results
Evaluation of IHC and MSD assays in myeloma cell lines
IHC is a popular assay in clinical PD biomarker studies.
To assess the sensitivity of the IHC assay, we conducted
a drug titration study by treating MM1s myeloma cells
with various amount of GDC-0941, and measured the
status of pS6 by IHC and MSD, a highly sensitive assay
for quantification. Figure 1a (top) shows the level of pS6
staining in MM1s cells in response to GDC-0941. Quan-
tification analysis indicated that MSD could detect pS6
down-regulation at 70nM of GDC-0941 compared to the
higher dose (220nM) detected by IHC (Figure 1a, bottom).
Thus, IHC is not a very sensitive assay compared to
MSD, where the down-regulation of pS6 revealed by
a b
Figure 1 Effects of drug wash-out on protein phosphorylation. (a). MM1s cells were treated with DMSO or GDC-0941 at indicated doses for
2 hours. Cell pellets were formalin fixed and paraffin embedded, and sectioned for pS6 staining (top). The level of pS6 was quantified by IHC and
MSD assays (bottom). (b). Two MM cell lines (MM1s and RPMI8226) were treated with DMSO or GDC-0941 (200nM) overnight, washed three times
and cultured in regular culture medium in the absence of GDC-0941 or DMSO. Cells were harvested at indicated times for MSD biochemical
assay. The ratio of the normalized pS6/tS6 between GDC-0941 and DMSO treatments was used to calculate the percentage of pathway
modulation. Data shown (a-b) are representative of at least three independent studies.
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response, but a lack of change by IHC does not indi-
cate the lack of PD response in clinical samples.
In a typical MM tumor PD study, isolation of tumor
cells from heterogeneous groups of cell populations in
BMA can take up to 2–3 hours with purification of bone
marrow mononuclear cells (BM MNC) and further
bead-based cell isolation. To determine the impact of
tumor cell isolation process on the integrity of phospho
protein signals, we performed a drug wash-out study
with GDC-0941 using the cultured myeloma tumor cell
lines and evaluated the extent of phosphorylation
change of S6, a downstream target of PI3K signaling
(Figure 1b, top). Remarkably, our MSD results revealed
that upon drug washout there was a cell line-specific
recovery of S6 phosphorylation over time. RPMI cells
quickly restored the previously reduced pS6 within half
an hour post drug wash-out, while MM1s cells
maintained knockdown of pS6 for up to 3 hours
(Figure 1b, bottom). The quick recovery of pS6 observed
herein suggests a similar scenario could potentiallyoccur in clinical BMA samples that undergo cell isola-
tion and could lead to false data interpretation.
Together, the IHC assay was less sensitive in terms of
signal quantification while the biochemical approach
(MSD) was less suitable to assess PD activities due to the
undesirable impact associated with cell isolation on the
protein phosphorylation in tumor cells.
Development of a pS6 phospho flow assay
Here we developed a phospho flow assay to assess pS6
pathway modulation in response to GDC-0941. Figure 2a
shows the shift of the high level of pS6 in tumor cells
towards baseline in response to GDC-0941. Similarly,
robust pS6-based PD pathway down-regulation has
been observed with other PI3K pathway inhibitors, but
not with non-PI3K pathway inhibitor when tested in this
study (data not shown). Quantification methodology is a
critical issue in phospho flow data analysis. We re-
evaluated the commonly used methods in phospho flow
studies, specifically percentage of phosphorylation-positive
cells (percentage) or mean fluorescence intensity (MFI),
a b
c d
Figure 2 Development of phospho flow assay. (a). PD response revealed by phospho flow analysis in MM1s cells. Note the peak shift of pS6
on the histogram in the GDC-0941-treated MM1s cells compared to DMSO. Baseline is defined based on isotype staining. (b). Cross-platform
comparison between MSD and phospho flow cytometry. iMFI methodology is used to calculate the pS6 signals (c and d). Intra-assay variation
studies demonstrate the absolute quantification of pS6 signals (c) and relative quantification (d), highlighting the coefficient of variation (CV).
Note that MM1s cells were treated with DMSO or a PI3K pathway inhibitor (tool compound) for 2 hours in the above studies. Data shown (a-d)
are representative of at least three independent studies.
Table 1 Basal levels of pS6 in MM tumor and immune
cells
Cell type CD marker Location pS6 PD response
Tumor cells CD45-; CD38+; CD138+ BMA +++ Robust
Monocytes CD45+; CD14+ PB, BMA +++ Moderate
B cells CD45+; CD20+ PB, BMA - N/A
T cells CD45+; CD3+ PB, BMA - N/A
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ately quantify fold changes in protein phosphorylation
upon drug treatment (Additional file 1: Figure S1). We
adopted a metric termed the integrated MFI (iMFI)
[14,15], defined as the percentage of pS6-positive tumor
cells multiplied by MFI of pS6-positive tumor cells, to
calculate the total functional phosphorylation signals in
subsequent PD studies.
To assess the sensitivity of phospho flow, we designed
a drug-titration study where MM1s cells were first
treated with various amounts of GDC-0941, and then
split for phospho flow analysis or MSD. Figure 2b shows
a strong correlation between the two platforms, demon-
strating comparable sensitivity for monitoring pathway
modulation with an IC50 of 8nM by phospho flow and
20nM by MSD. Intra-assay variation studies showed
that the phospho flow assay is highly reproducible with
only minor variability (Figure 2c and 2d).
Development of tumor PD and surrogate PD biomarkers
To take advantage of the resolving power of simultaneous
intracellular staining of the phospho-epitope and surfacestaining with immunophenotypic markers, we further de-
veloped a 7-color antibody panel that allows for PD moni-
toring of S6 protein phosphorylation in tumor and
surrogate tissues using BMA and/or whole blood (Table 1).
We performed a dose-titration study using MM patient-
derived BMA and PB. In addition to myeloma tumor cells
and monocytes as shown in Figure 3a, we also gated on B
cells (CD45+; CD20+) and T cells (CD45+; CD3+).
Phospho flow analysis showed that pS6 was highly
expressed in tumor cells and monocytes in contrast to the
barely detected pS6 in B and T cells (Figure 3a, Table 1).
Both tumor cells and monocytes exhibited a dose-
dependent pS6 down-regulation in response to GDC-0941
ab c
Figure 3 Development of tumor PD and surrogate PD biomarkers using phospho flow assay. (a). Gating strategy of tumor and surrogate
tissues in pS6 phospho flow study using BMA and PB obtained from myeloma patients. Representative scheme is shown for myeloma tumor cells
(CD45-; CD38+; CD138+) in BMA and monocytes (CD45+; CD14+) in PB and BMA. FACS, i.e., fluorescence-activated cell sorting, is a specialized
type of flow cytometry. (b and c). GDC-0941 dose-dependent PD response. Patient-derived BMA and PB were treated with GDC-0941 at indicated
doses ex vivo for 2 hours. Phospho flow analysis demonstrated the GDC-0941 dose-dependent tumor PD response in histogram (b) and % of
pS6 baseline signals in tumor cells and monocytes (c). Data shown are representative of at least three independent studies.
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Of note, tumor cells and BMA-derived monocytes were
more sensitive when compared to blood monocytes (IC50:
31nM in tumor cells, 26nM in BMA monocytes, and
718nM in PB monocytes) (Figure 3c).
Development of a one-shot sample handling protocol for
clinical trials
The stability of phospho-epitopes is of particular concern
when applying phospho flow in the clinic. MM BMA and
blood samples in clinical trials are often freshly collected
and directly shipped under ambient conditions for down-
stream studies. To assess whether the stability of pS6 in
unfixed cells is affected by the ambient conditions, weperformed a tumor cell spike-in study by adding tumor
cells into PB and stored them at room temperature. Of
note, phospho flow analysis demonstrated that the basal
level of pS6 dropped dramatically over time in both tumor
cells (Figure 4a) and monocytes (data not shown),
suggesting caution of the handling of unfixed cells under
ambient conditions and emphasizing the value of immedi-
ate cell fixation to preserve the phosphorylation of S6.
Sample collection and handling is more complicated in
clinical laboratories than in preclinical settings. Every step
of sample handling in clinical laboratories may increase
the risk of a false PD readout. To simplify the process, we
developed a one-shot sample handling procedure after
testing 15 conditions of sample fixing and handling. The
ac
b
Figure 4 Development of one-shot sample handling protocol. (a). Ambient storage conditions impair the pS6 status over time. Y-axis refers
to % of pS6 baseline signals. (b). The one-shot sample handling protocol provided well-preserved pS6 signals for 24 hrs. (c). An overview of the
phospho flow-based PD study proposed for clinical trials. Data shown (a-b) are representative of at least three independent studies.
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or whole blood into a tube containing lysis/fixation buffer
and incubate for 10 minutes at RT, followed by immediate
storage/shipment at 4°C without any need for centrifuga-
tion, aspiration, or washing procedures. When compared
to results found with fresh tumor samples, the pS6 signal
was well preserved for at least 24 hours in fixative without
noticeable loss in signal strength (Figure 4b). Thus, fix-
ation of BMA and PB at RT followed by storage and ship-
ment at 4°C produced optimal results for pS6 staining. An
overview of the optimal clinical phospho flow-based PD
assay is presented in Figure 4c.
Discussion
Phospho flow can provide rich information in monitoring
PI3K signaling cascades in complex cell populations such
as BMA and PB, eliminating the need for any cell purifica-
tion used in traditional biochemical studies. Following the
elegant work by Nolan’s group [16], this study has further
optimized phospho flow PD assay from the perspective of
clinical applications. Specifically, immediate fixation of
BMA or PB provides the best preservation of protein
phosphorylation in a more physiological environmentconsidering the nature of myeloma to pathogenesis, which
is heavily influenced by tumor-stroma interaction [1]. A
case in point is the enhanced drug sensitivity in BM
monocytes that could be associated with cytokine stimula-
tion as well as stromal and/or microenvironment bone
marrow factors that are absent or present in low concen-
trations in PB. The one-shot sample handling proced-
ure is extremely attractive because of its simplicity
and reproducibility, clinical applicability, thereby min-
imizing changes associated with cell manipulation bias
while maximizing the accuracy of PD readouts. These
attributes are particularly important for multicenter
clinical trials. The incorporation of the 7-color anti-
body panel into a single staining tube further enables
multi-parameter data acquisition and analysis, redu-
cing experimental time and inter-experiment variabil-
ity, while allowing PD analysis in multiple cell types.
iMFI-based data analysis provided an accurate quanti-
fication of fold changes in phosphorylation in response to
GDC-0941. Finally, cross-platform comparison revealed a
strong correlation of assay sensitivity between phospho
flow and MSD, whereas IHC assay was less sensitive in
terms of quantification.
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ment) is a challenge in clinical trials. In this regard, PB
provides an easily obtainable source to serially monitor
S6 phosphorylation, generating reliable and reprodu-
cible PD readouts from monocytes and sometimes circu-
lating tumor cells. The surrogate PD assay developed here
complements the use of a platelet rich plasma (PRP) assay,
another sensitive surrogate PD biomarker assay currently
used in PI3K clinical trials. Despite their threshold
discrepancy (Figure 3c), PB monocyte-based surrogate
biomarkers (IC50: 718nM) could be informative given that
the clinically achievable exposures of GDC-0941 are be-
tween 800–3000 nM at maximum plasma concentration
(Cmax).
We envision that phospho flow and its derivative
CyTOF, which merges flow cytometry with mass spec-
trometry, potentially have more general applications in
oncology biomarker studies, providing solutions to ad-
dress the therapeutic effects in heterogeneous cell popula-
tions that are often difficult to study biochemically. The
protocol outlined here serves as a starting point for other
phospho-epitopes, though challenges remain in that the
approach will require extensive optimization of both the
protocol and the reagents used to qualify additional end-
points for emerging clinical applications.
Conclusions
We developed a robust PD assay and evaluated tumor and
surrogate PD biomarkers for the clinical evaluation of
GDC-0941 in MM. To our knowledge, this is the first re-
port of an easily implemented clinical PD assay that incor-
porates an unbiased one-shot sample handling protocol,
all (staining)-in-one (tube) phospho flow staining protocol,
and an integrated modified data analysis for PD monitor-
ing of kinase inhibitors in relevant cell populations in
BMA and PB. The tumor and surrogate PD biomarkers
described here may provide useful information for dose
selection and confirm pathway modulation in response to
PI3K inhibitor treatment, as well as potentially identify
optimal combinations of targeted agents in early clinical
trials.
Additional file
Additional file 1: Figure S1. Evaluation of percentage, MFI, and iMFI by
phospho flow. In this hypothetical study, cells were treated with DMSO
or GDC-0941. Phospho flow revealed two types of PD responses in
Scenario 2 and 3. The average amount of pS6 fluorescence intensity is
labeled on each cell (circle). X axis refers to the fluorescence intensity of
pS6, and y axis the CD marker.
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